Snyder, Robert W., M.D., Ph.D., P.C.: Clinical Trials

3 completed, 1 terminated, 1 withdrawn. 5 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	5	Completed 3, Terminated 1, Withdrawn 1

Follow Snyder, Robert W., M.D., Ph.D., P.C.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration carbidopa-levodopa 25-100 mg, placebo for carbidopa-levodopa 25-100 mg - Age-related Macular Degeneration	Phase 2	Withdrawn	Snyder, Robert W., M.D., Ph.D., P.C.		2019-09-01	2019-04-05
Carbidopa-Levodopa in Dry AMD With Geographic Atrophy carbidopa-levodopa - Age Related Macular Degeneration	Phase 2	Terminated	Snyder, Robert W., M.D., Ph.D., P.C.	7	2018-07-01	2024-04-25
Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD) carbidopa-levodopa 25-100 mg - Macula; Degeneration, Retina	Phase 2	Completed	Snyder, Robert W., M.D., Ph.D., P.C.	35	2017-08-01	2025-09-12
Carbidopa-levodopa in Neovascular AMD carbidopa-levodopa 25-100 mg tablets - Age-related Macular Degeneration	Phase 2	Completed	Snyder, Robert W., M.D., Ph.D., P.C.	20	2017-05-02	2025-09-12
Dose Ranging Study of Carbidopa-levodopa Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet - Age-related Macular Degeneration	Phase 2	Completed	Snyder, Robert W., M.D., Ph.D., P.C.	35	2017-05-02	2025-09-12

Conditions studied

Macular Degeneration (4)

Interventions

carbidopa, levodopa drug combination (5)

Countries

United States (5)

Top investigators

Robert W Snyder, MD, PhD (5)  ·  Timothy C Fagan, MD (4)